Strong Response To Live Blog On Arena (ARNA)

TheStreet.com's senior biotech columnist Adam Feuerstein had a live blog today, in which he discussed the Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) ruling from the FDA on its weight loss drug, lorcaserin.

The blog had more 5,000 readers, and almost 350,000 page views, an unprecedented number of page views.

This is a tremendous amount of traffic, and goes to show that the web and new forms of social media are here to stay for financial news.

Congratulations Adam on the success of the blog.